NIP
TRIL

Nicholas Investment Partners’s Trillium Therapeutics Inc. TRIL Stock Holding History

Nicholas Investment Partners’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-1,381,983
Closed -$13.4M – 215
2021
Q2 		$13.4M Buy
1,381,983
+35,230
+3% +$332K 0.84% 44
2021
Q1 		$14.5M Buy
1,346,753
+579,369
+75% +$7.17M 1.01% 39
2020
Q4 		$11.3M Buy
767,384
+193,755
+34% +$2.79M 0.87% 40
2020
Q3 		$8.15M Buy
+573,629
New +$5.72M 0.88% 41
2016
Q1 		– Sell
-27,095
Closed -$342K – 346
2015
Q4 		$342K Buy
27,095
+315
+1% +$4.38K 0.02% 280
2015
Q3 		$349K Buy
26,780
+19,476
+267% +$358K 0.03% 292
2015
Q2 		$159K Buy
+7,304
New +$167K 0.01% 304

Other funds holding TRIL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
OPU
Omni Partners US Irvine, California $1.95B AUM
UOC
UBS O'Connor Chicago, Illinois $3.38B AUM 63.08% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return

Nicholas Investment Partners's TRIL Position: Q3 2021 in Review

Nicholas Investment Partners sold out of Trillium Therapeutics Inc. (TRIL) in Q3 2021, closing a stake of 1,381,983 shares — an estimated $13.4M sold.

Nicholas Investment Partners first reported a position in TRIL in Q2 2015 and held it in 7 quarters. The position peaked at $14.5M in Q1 2021. 182 funds tracked by Wall St. Rank hold TRIL as of Q3 2021.

  • Nicholas Investment Partners reported no remaining Trillium Therapeutics Inc. position as of Q3 2021 after selling out during the quarter.
  • Nicholas Investment Partners sold 1,381,983 Trillium Therapeutics Inc. shares in Q3 2021, an estimated $13.4M.
  • Nicholas Investment Partners first reported a position in Trillium Therapeutics Inc. in Q2 2015 and held it in 7 quarters.
  • Nicholas Investment Partners's Trillium Therapeutics Inc. position peaked at $14.5M in Q1 2021.
  • 182 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q3 2021.

Based on Nicholas Investment Partners's 13F filing for Q3 2021, filed 15 Nov 2021.